The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation in Stage III disease) which showed improved survival for patients in the imm...
Main Authors: | Kirstin Perdrizet, Parneet K. Cheema |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/28/6/451 |
Similar Items
-
Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
by: Arani Sathiyapalan, et al.
Published: (2023-10-01) -
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments
by: Alessandra Ferro, et al.
Published: (2022-11-01) -
Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
by: Min Fang, et al.
Published: (2023-01-01) -
Lobe‐specific analysis of perioperative chemotherapy for non‐small cell lung cancer patients
by: Xi Lei, et al.
Published: (2023-08-01) -
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
by: Chiara Lazzari, et al.
Published: (2023-03-01)